Therapeutic area

Hematology

Non-malignant blood disorders, hemoglobinopathies, coagulopathies, and complement-mediated hematologic diseases.

Core & active disease programs

Sickle Cell Disease

$3.4B+ attributable cost

18 assets · 2 indications

Provisional & emerging programs (9)Early clinical pipeline & single-asset indications

Graft-versus-Host Disease

4 assets· 3 indications

Beta-Thalassemia

Immune Thrombocytopenia

Iron Deficiency Anemia

Paroxysmal Nocturnal Hemoglobinuria

Pyruvate Kinase Deficiency

Thrombotic Microangiopathy

All assets in Hematology